Comparing Nutex Health (NASDAQ:NUTX) & Bausch + Lomb (NYSE:BLCO)

Nutex Health (NASDAQ:NUTX) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Earnings and Valuation

This table compares Nutex Health and Bausch + Lomb”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutex Health	$875.26 million	0.75	$70.79 million	$8.98	10.45
Bausch + Lomb	$5.10 billion	1.07	-$360.00 million	($1.02)	-15.08

Nutex Health has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

5.3% of Nutex Health shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 44.7% of Nutex Health shares are owned by company insiders. Comparatively, 0.8% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Nutex Health has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Nutex Health and Bausch + Lomb, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutex Health	0	1	2	0	2.67
Bausch + Lomb	1	10	4	0	2.20

Nutex Health presently has a consensus target price of $252.50, suggesting a potential upside of 169.16%. Bausch + Lomb has a consensus target price of $18.25, suggesting a potential upside of 18.65%. Given Nutex Health’s stronger consensus rating and higher probable upside, equities analysts plainly believe Nutex Health is more favorable than Bausch + Lomb.

Profitability

This table compares Nutex Health and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutex Health	7.34%	17.67%	7.37%
Bausch + Lomb	-7.06%	2.77%	1.31%

Summary

Nutex Health beats Bausch + Lomb on 9 of the 14 factors compared between the two stocks.

About Nutex Health

Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.